贝伐珠单抗对结直肠癌细胞串珠素表达的影响  

Effect of bevacizumab on perlecan expression in colorectal carcinoma cells

作　　者：刘洪金[1,2] 贾森浩[3] 张莹莹[4] 张芦芦 付艳[1] 张力文[6] 吴柏寿 王晓朋[8] 杜楠[1] 

机构地区：[1]解放军总医院第一附属医院肿瘤二科,北京100048 [2]解放军302医院肝脏肿瘤中心,北京100039 [3]解放军总医院血管外科,北京100853 [4]界首市第一人民医院妇产科,安徽阜阳236505 [5]界首市第一人民医院神经内科,安徽阜阳236505 [6]浙江大学医学院附属邵逸夫医院肿瘤外科,浙江杭州310016 [7]解放军第535医院肿瘤科,湖南怀化418000 [8]解放军总医院第一附属医院神经外科,北京100048

出　　处：《实用肿瘤杂志》2015年第4期325-330,共6页Journal of Practical Oncology

基　　金：北京科委首都医疗特色项目(Z13110700221 3040)

摘　　要：目的探究贝伐珠单抗对结直肠癌细胞串珠素表达的影响。方法将处于对数生长期的肿瘤细胞(HCT116和HT29细胞)分为两组:对照组和实验组(加入终浓度为400μg/L的贝伐珠单抗48小时),采用RTPCR检测结直肠癌细胞串珠素mRNA表达。将同一批处于对数生长期的肿瘤细胞分为6组,一组为对照组,其余5组实验组分别加入终浓度为25、50、100、200和400μg/L的贝伐珠单抗,48小时后ELISA检测直肠癌细胞及培养液上清的串珠素蛋白水平,Western blot检测结直肠癌细胞串珠素的蛋白表达。结果与对照组比较,实验组肿瘤细胞串珠素mRNA及蛋白水平均上调(均P<0.05)。在细胞培养液中,与对照组比较,实验组的串珠素蛋白水平未出现显著变化(P>0.05)。结论贝伐珠单抗引起结直肠癌细胞串珠素mRNA和蛋白表达的上调,但未引起细胞培养液中串珠素蛋白的显著变化。Objective To investigate the effect of bevacizumab on perlecan expression in colorectal carcinoma cells. Methods Colorectal carcinoma HCTll6 and HT29 cells in logarithmic phase were treated with bevaeizmab （final concentration 400 μg/L） for 48 h. The level of pedecan mRNA was detected by RT-PCR. Colorectal carcinoma cells were treated with 0, 25, 50, 100, 200 and 400 μg/L bevacizumab for 48 h. The level of pedecan protein in conditioned media was detected with ELISA, and the expression of perlecan in colorectal cancer cells was detected with Western blot. Results Compared with the control, the expressions of pedecan mRNA and protein in bevacizumab treated cells were both significantly up-regulated （ both P 〈 0.05 ）. However, there was no significant change of perlecan protein level in conditioned media in bevacizuamb treated cells compared with the control （ P 〉 0.05 ）. Conclusion Bevacizumab can up- regulate the expression of perlecan mRNA and protein level in colorectal carcinoma cells, but can not change perlecan protein level in conditioned media.

关 键 词：结直肠肿瘤 抗体 单克隆/治疗应用 逆转录聚合酶链反应 类肝素硫酸蛋白聚糖类/分析 肿瘤细胞 培养的 

分 类 号：R735.34[医药卫生—肿瘤]